ACQUISITION (Tables)

6 Months Ended

Jun. 30, 2012

ACQUISITION [Abstract]

Total purchase price

The following table summarizes the accounting treatment of the purchase price paid (in thousands):

Acquisition consideration	$	306,841
Share-based compensation expense		8,265
Total purchase price	$	315,106

Provisional fair values of assets acquired, liabilities assumed and goodwill

The determination of the fair values of the assets acquired and liabilities assumed has been prepared on a provisional basis and changes to that determination may occur as additional information becomes available. The following table summarizes the provisional fair values of assets acquired, liabilities assumed and goodwill (in thousands):

Cash and cash equivalents	$	7,095
Accounts receivable, net		9,488
Inventories		52,060
Prepaid expenses and other assets		7,844
Property and equipment		5,969
Intangible assets		159,755
Other non-current assets		1,769
Identifiable assets acquired		243,980
Accounts payable and accrued liabilities		(18,681	)
Deferred tax liability		(55,542	)
Other non-current liabilities		(3,241	)
Identifiable liabilities acquired		(77,464	)
Goodwill		140,325
Acquisition consideration	$	306,841

Definite-lived intangible assets acquired and their estimated useful lives

The following table summarizes the provisional fair value of definite-lived intangible assets acquired at the Acquisition Date and their estimated useful lives (in thousands, except for estimated useful lives):

	Provisional		Estimated
	Fair Value		Useful Life
Purchased intangible assets
Customer relationships	$	85,700	12 years
Developed technologies		50,900	12 years
Trademarks and tradenames		14,600	5 years
Other contractual agreements		2,800	2 years
License fees		5,755	13 years
Total	$	159,755

Unaudited pro forma financial information

The following unaudited pro forma financial information presents the combined results of operations for the three and six months ended June 30, 2012 and 2011 as if the Acquisition had been completed on January 1, 2011, with adjustments to give effect to pro forma events that are directly attributable to the Acquisition. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the consolidation of the operations of the Company and eBioscience. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the Acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands, except per share data):

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Revenues	$	83,385		$	82,380		$	167,396		$	173,913
Net income (loss)		(9,578	)		(18,584	)		(19,038	)		25,700
Basic earnings per share		(0.14	)		(0.27	)		(0.27	)		0.36
Diluted earnings per share		(0.14	)		(0.27	)		(0.27	)		0.32